
Form PTO-14	149		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. 147/49991		Serial No. TBA		
				Applicants Johannes HEBEBRAND, et al.					
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					Group			
	U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date (if appropriate)		
	AA					<u> </u>			
FOREIGN PATENT DOCUMENTS									
		Document	Date	Country	Class	Sub- class	Translation Yes No		
	AB	EP0138441	04/1985	Europe			Yes		
	AC	WO9800130	01/1998	WO			Yes		
	OTHER	DOCUMENTS (Inclu	ding Author	c, Title, Date, P	ertinen	Pages,	Etc.)		
	AD	Karl M. WILBUR, "Electrometric and Colorimetric Determination of Carbonic Anhydrase" Journal of Biological Chemistry, Vol. 176, 1948							
	AE	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors and their therapeutic potential" Ashley Publications Ltd., pp. 1354-3776, 200 MK HELLERSTEIN, "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1993							
	AF								
	AG	Bruce E. MARYANOFF, "Structure-Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with Cyclic Sulfate Derivatives" J. Med. Chemistry, Vol. 41, pp. 1315-1343, 1998							
	AH	Susanna J. DODGSON, "Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes" Epilepsia, Vol. 41, 2000 Y. Pocker, J.T. STONE, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase. The Enzyme-Catalyzed Hydrolysis of ρ-Nitrophenyl Acetate" Journal of the American Chemistry Society, 87:23, 1965							
	AI								
	AJ	Robert W. HECK, "Catalytic Properties of Mouse Carbonic Anhydrase V*" The Journal of Biological Chemistry, Vol. 269, No. 40, 1994							
EXAMINER				DATE CONSIDERED					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.									



Form PTO-14	149	II S. Department of Common	Atty. Docket No.	Serial No.			
FORM P10-1449		U.S. Department of Commerce Patent & Trademark Office	147/49991	TBA			
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicants Johannes BEBEBRAND, et al.				
			Filing Date Herewith	Group			
(THER	DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)			
	AK Gautam SANYAL, "Thermodynamics of Carbonic Amhydrase Cataly Journal of Biological Chemistry, Vol. 256, No. 2, 1981						
	AL	James E. P. TOMAN, "Properties of Maximal Seizures, and their Alteration by Anticonvulsant Drugs and other Agents" University of Utah School of Medicine, 1946					
	AM	Y. POCKER, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase III. Kinetic Studies of the Enzyme-Catalyzed Hydrolysis of ρ-Nitrophenyl Actate" Biochemistry, Vol. 6, No. 3, 1967					
	AN	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors-Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV" Eur. J. Med. Chemistry, Vol. 33, 1998					
	AO	Graham CHEN, "Evaluation of Five Methods for Testing Anticonvulsant Activities" Department of Pharmacology, Parke, Davis & Co., 1954					
	AP	Andrea SCOZZAFAVA, "Carbonic Anhydrase Inhibitors: Synthesis of Water-Soluble, Aminoacyl/Dipeptidyl Sulfonamides Possessing Long-Lasting Intraocular Pressure-Lowering Properties via the Topical Route" J. Med. Chemistry, Vol. 42, 1992					
	AQ	Raja G. KHALIFAH, "The Carbon Dioxide Hydration Activity of Carbonic Anhydrase" The Journal of Biological Chemistry, Vol. 246, No. 8, 1971					
	AR	Stacy A. HAZEN, "Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes" The FASEB Journal, 1995					
	AS	Bruce E. MARYANOFF, "Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-B-D-fructopyranose Sulfamate and Related Compounds" American Chemistry Society, 1987					
EXAMINER			DATE CONSIDERED				
EXAMINER:	line	cial if citation considered, whethe through citation if not in confor communication.	r or not citation is in confor	mance with MPEP 609; Draw lude copy of this form with			

OBEST AVAILABLE COPY

 \bigcirc

FORM PTO-1449
U.S. Department of Commerce Patent & Trademark Office

Attorney Docket No. 147/49991

Applicant: Johannes HEBEBRAND, et al.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Filing Date July 18, 2001

Group

				odry	10, 2001					
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number	Date		Name ·	Class	Sub- Class	Filing Date (if appropriate)		
	AA									
	АВ									
	AC									
	AD									
	AE									
	AF									
	AG		,							
	АН									
	AI					ļ				
	AJ					<u> </u>				
			FOREI	GN PAT	TENT DOCUMENTS					
Examiner Initial		Document Number	Date		Name	Class	Sub- Class	TRANSLATION Yes No		
	AK									
	AL									
	AM									
	AN									
	AO									
	AP									
	OTHE	R DOCUMENTS (Including A	uthor,	Title, Date, P	ertinent Pa	ages,	etc.)		
	AQ	Claudiu T. SUPURAN, et al., "Carbonic anhydrase inhibitors and their therapeutic potential" Expert Opinion on Therapeutic Patents, 2000								
	AR	M. K. HELLERSTEIN, et al., "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1999								
	AS									
EXAMINER DATE CONSIDERED										
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.										